Literature DB >> 25529419

An investigation of the efficacy of a polyvalent mastitis vaccine using different vaccination regimens under field conditions in the United Kingdom.

A J Bradley1, J E Breen2, B Payne3, V White3, M J Green4.   

Abstract

Vaccination can play a useful role in mastitis control programs, although there is a relative dearth of large, well-controlled field efficacy studies. This paper presents the findings on the use of a commercially available vaccine (Startvac, Hipra UK Ltd., Nottingham, UK) on commercial units under UK field conditions. In total, 3,130 cows were recruited from 7 farms and were randomly allocated, within farm, to 1 of 3 groups. The first group received the vaccine following the label regimen, the second group was vaccinated every 90 d following an initial vaccination course, and the third group was left unvaccinated to act as controls. Vaccine efficacy was assessed in the first 120 d of lactation. Data were available for analysis from 1,696 lactations in 1,549 cows. In total, 779 cases of clinical mastitis occurred in the 3 study groups, and we detected no significant difference in the incidence or prevalence of clinical or subclinical mastitis between any of the 3 groups. Mastitis vaccination following the label regimen was associated with a significant reduction in the severity of clinical cases. Cows in this group were at significantly decreased odds of developing clinical mastitis presenting with more than just milk changes [odds ratio: 0.58; 95% confidence interval (CI): 0.35-0.98]. Similarly, each additional vaccination resulted in a cow being at decreased odds of developing clinical mastitis presenting with more than just milk changes (odds ratio: 0.87; 95% CI: 0.77-0.98). Although no cows were culled because of severe mastitis in either of the vaccinated groups, we detected no significant difference in the mastitis-related culling rate between groups. Analysis of milk production data demonstrated that, on average, cows on the label regimen produced a higher volume of milk (231 L; 95% CI: 104.1-357.4) and more milk solids (12.36 kg; 95% CI: 3.12-21.60) than unvaccinated cows in the first 120 d of lactation. Conservative analysis suggested that a return on investment of 2.57:1 could be expected under UK conditions based on increased milk yield alone.
Copyright © 2015 American Dairy Science Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Escherichia coli; coliform; mastitis; milk production; vaccination

Mesh:

Substances:

Year:  2014        PMID: 25529419     DOI: 10.3168/jds.2014-8332

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  21 in total

1.  Immunogenicity of a Staphylococcus aureus-cholera toxin A2/B vaccine for bovine mastitis.

Authors:  N Misra; T F Wines; C L Knopp; R Hermann; L Bond; B Mitchell; M A McGuire; J K Tinker
Journal:  Vaccine       Date:  2018-05-05       Impact factor: 3.641

2.  Prevention of Bovine Mastitis through Vaccination.

Authors:  A Zhylkaidar; K Oryntaev; A Altenov; E Kylpybai; E Chayxmet
Journal:  Arch Razi Inst       Date:  2021-11-30

3.  Assessment of listing and categorisation of animal diseases within the framework of the Animal Health Law (Regulation (EU) No 2016/429): antimicrobial-resistant Staphylococcus aureus in cattle and horses.

Authors:  Søren Saxmose Nielsen; Dominique Joseph Bicout; Paolo Calistri; Elisabetta Canali; Julian Ashley Drewe; Bruno Garin-Bastuji; José Luis Gonzales Rojas; Christian Gortázar; Mette Herskin; Virginie Michel; Miguel Ángel Miranda Chueca; Barbara Padalino; Paolo Pasquali; Helen Clare Roberts; Hans Spoolder; Karl Ståhl; Antonio Velarde; Arvo Viltrop; Christoph Winckler; Francesca Baldinelli; Alessandro Broglia; Lisa Kohnle; Julio Alvarez
Journal:  EFSA J       Date:  2022-05-10

4.  A risk-oriented evaluation of biofilm and other influencing factors on biological quality of drinking water for dairy cows.

Authors:  Jason J Hayer; Céline Heinemann; Benedikt G Schulze-Dieckhoff; Julia Steinhoff-Wagner
Journal:  J Anim Sci       Date:  2022-05-01       Impact factor: 3.338

5.  Efficacy of a polyvalent mastitis vaccine against Staphylococcus aureus on a dairy Mediterranean buffalo farm: results of two clinical field trials.

Authors:  Jacopo Guccione; Antonella Pesce; Massimo Pascale; Caterina Salzano; Gianni Tedeschi; Luigi D'Andrea; Angela De Rosa; Paolo Ciaramella
Journal:  BMC Vet Res       Date:  2017-01-19       Impact factor: 2.741

6.  Prediction of Streptococcus uberis clinical mastitis risk using Matrix-assisted laser desorption ionization time of flight mass spectrometry (MALDI-TOF MS) in dairy herds.

Authors:  Simon C Archer; Andrew J Bradley; Selin Cooper; Peers L Davies; Martin J Green
Journal:  Prev Vet Med       Date:  2017-05-17       Impact factor: 2.670

7.  A strategy to estimate the rate of recruitment of inflammatory cells during bovine intramammary infection under field management.

Authors:  J Detilleux
Journal:  BMC Vet Res       Date:  2017-06-08       Impact factor: 2.741

8.  Immunization routes in cattle impact the levels and neutralizing capacity of antibodies induced against S. aureus immune evasion proteins.

Authors:  Eveline Boerhout; Manouk Vrieling; Lindert Benedictus; Ineke Daemen; Lars Ravesloot; Victor Rutten; Piet Nuijten; Jos van Strijp; Ad Koets; Susanne Eisenberg
Journal:  Vet Res       Date:  2015-09-28       Impact factor: 3.683

9.  Vaccination against Staphylococcus aureus mastitis in two Swedish dairy herds.

Authors:  Håkan Landin; Marie Jansson Mörk; Maria Larsson; Karin Persson Waller
Journal:  Acta Vet Scand       Date:  2015-11-25       Impact factor: 1.695

Review 10.  Mastitis vaccines in dairy cows: Recent developments and recommendations of application.

Authors:  Zuhair Bani Ismail
Journal:  Vet World       Date:  2017-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.